MGH Nuclear Medicine and Molecular Imaging/Gordon PET Core Available PET Radiopharmaceuticals for Human Use

Revision: October 2017

F-18 FDG* (tumour metabolism/hypometabolism) Florbetaben** (amyloid imaging) Flutemetamol** (amyloid imaging) Florbetapir** (amyloid imaging) Fluciclovine** (tumor metabolism/prostate cancer imaging) Sodium Fluoride** (bone imaging) FES (estrogen receptor)† Flortaucipir [T807] (tau protein)† FPEB (mGlur5)‡ BFPET (myocardial perfusion) † GE180 (TSPO/PBR)† FLT (cellular proliferation)† THK 5351/GE-216 (tau protein)† FMISO (hypoxia)† MK-6240 (tau protein) † GE179 (NMDA receptor)‡

C-11 PiB (amlyoid)† Altropane (Dopamine transport)‡ Raclopride (D2/D3 receptor imaging) † Methionine (amino acid uptake)† Acetate (fatty acid synthase) ‡ CO (gas for labeling red blood cells in vivo) ‡ Rolipram (PDE-4 receptor imaging) ‡ P943 (5-HT1B) ‡ PBR-28 (TSPO/PBR)† (S,S)-[11C]Methylreboxetine (MeNR/MRB)‡ – targets norepinephrine transporter

N-13 Ammonia* N2 in Saline (lung perfusion imaging) ‡

Ga-68 DOTATATE** (neuroendocrine tumor imaging)

O-15 15 C O2 (blood flow imaging) ‡

*FDA approved, MGH PET Center holds FDA marketing authorization **FDA approved, available through local commercial nuclear pharmacies †Active IND held by MGH Gordon PET Core ‡Available under Radioactive Drug Research Committee (RDRC) oversight

MGH Nuclear Medicine and Molecular Imaging/Gordon PET Core Available PET Radiopharmaceuticals for Human Use

Revision: October 2017

The MGH Gordon PET Core can validate a radiopharmaceutical for clinical research use. Please send inquiries to Daniel Yokell, Associate Director, Radiopharmacy and Regulatory Affairs, MGH Gordon PET Core. Email [email protected] or 617-643-7541.

*FDA approved, MGH PET Center holds FDA marketing authorization **FDA approved, available through local commercial nuclear pharmacies †Active IND held by MGH Gordon PET Core ‡Available under Radioactive Drug Research Committee (RDRC) oversight